CN106214717A - A kind of for compound eye drops treating mycotic scleritis and preparation method thereof - Google Patents
A kind of for compound eye drops treating mycotic scleritis and preparation method thereof Download PDFInfo
- Publication number
- CN106214717A CN106214717A CN201610790882.5A CN201610790882A CN106214717A CN 106214717 A CN106214717 A CN 106214717A CN 201610790882 A CN201610790882 A CN 201610790882A CN 106214717 A CN106214717 A CN 106214717A
- Authority
- CN
- China
- Prior art keywords
- eye drops
- compound eye
- scleritis
- chanterelle
- treating mycotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/237—Notopterygium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of for compound eye drops treating mycotic scleritis and preparation method thereof, described compound eye drops becomes to be grouped into: natamycin 0.01～0.03%, chanterelle mycelium powder 1～2%, Herba Emiliae alkaloid 0.1～0.2%, taurine 0.05～0.08%, jasminoidin 0.2～0.4%, hyaluronate sodium 0.6～0.9%, paeonol 0.3～0.4%, Rhizoma Et Radix Notopterygii volatile oil 0.06～0.09%, glycyrrhizic acid dipotassium 0.12～0.24%, flucytosine 0.02～0.03%, Radix Bupleuri total saponin 0.2～0.4%, vitamin A 2～4%, surplus is water for injection.The compound eye drops of the present invention has stronger antifungal activity, and has the effect of Antipyretic, further enhances body anti-infection ability, improves immunity of organisms, and evident in efficacy to mycotic scleritis, safe secondary effect is little.
Description
Technical field
The present invention relates to ophthalmic remedy technical field, be specifically related to a kind of compound recipe eye drip for treating mycotic scleritis
Liquid and preparation method thereof.
Background technology
Mycotic scleritis is by eukaryotic microorganisms, reduces at body's immunity, and particularly cellular immune function reduces
Time, invasion and attack tissue and cause furious, photophobia, shed tears, ophthalmalgia, visual deterioration and the ocular disease of conjunctival sac secretions.
Mycotic scleritis shows as the necrotizing anterior scleritis being slowly in progress.Onset is slow.Cardinal symptom has furious, fear
Light, shed tears, ophthalmalgia, visual deterioration and conjunctival sac secretions.Comparing with bacillary scleritis, irritation is relatively light, the course of disease is longer.
Major part mycotic scleritis patient has pain, can be confined to eye, it is possible to along nervi trigeminus branching to temporo side head and volume
Portion, is easily misdiagnosed as migraine, sinusitis, even cerebroma etc..Clinical sign: pathological changes sclera limitation inflammatory infiltration, color in early days
Dark red, sclera focus and may occur in which lamellar avascular area about, it is the key sign of necrotizing anterior scleritis, should carefully examine
Look into.Pathological changes can develop to different directions, absorbable limitation, also can be in progress into large area necrosis, and sclera of getting involved can be downright bad thinning, bad
Sclera edema around dead band.Episclera vasodilation is tortuous, displacement.After healing, necrotic area sclera is belittled, in dusty blue outward appearance,
Tunica uvea can be exposed, but staphyloma seldom occurs.With the fungal infection of Near tissue, common with keratitis.Show as cornea
Medium Culture abscess, leukocyte infiltration or the shallow table ulcer that central authorities or other central authorities isolate or are dispersed in, matt in dirty fur shape, ulcer edge
Infiltration or shallow ridges in featheriness annular, obvious with surrounding tissue boundary, around there is isolated circular point-like to infiltrate, be referred to as " satellite
Stove ".Sometimes there is immune ring around ulcer.The fungal keratitis patient of 50% can form sticky hypopyon.
Summary of the invention
The technical problem to be solved in the present invention be to provide a kind of compound eye drops for treating mycotic scleritis and
Preparation method.
The technical scheme is that a kind of compound eye drops for treating mycotic scleritis, one-tenth is grouped into: that
His mycin 0.01～0.03%, chanterelle mycelium powder 1～2%, Herba Emiliae alkaloid 0.1～0.2%, taurine 0.05～
0.08%, jasminoidin 0.2～0.4%, hyaluronate sodium 0.6～0.9%, antioxidant 0.005～0.009%, surface activity
Agent 0.2～0.4%, isotonic agent 0.01～0.02%, surplus are water for injection.
Further, described compound eye drops becomes to be grouped into and also includes: paeonol 0.3～0.4%, Rhizoma Et Radix Notopterygii volatile oil
0.06～0.09%, glycyrrhizic acid dipotassium 0.12～0.24%.
Further, described compound eye drops becomes to be grouped into and also includes: flucytosine 0.02～0.03%, the total soap of Radix Bupleuri
Glycosides 0.2～0.4%, dehydroretinol～4%.
Further, described chanterelle mycelium powder is to be pulverized prepared by chanterelle by the mycelium that fermentation culture generates
's.Detailed process is: first by quality 1:1, Rhizoma Solani tuber osi and the Folium Pini of peeling stripping and slicing are joined the steaming relative to Rhizoma Solani tuber osi 5 times amount
Distilled water is boiled, filters reserved filtrate and continue, be subsequently adding and dissolve relative to agar and the glucose of Rhizoma Solani tuber osi 1/10, then exist
0.1MPa, 120 DEG C of sterilizings 30～40min, then preserve 24～36h at 37 DEG C, make culture medium, is subsequently adding PH regulator and adjusts
PH to 6, adds a small amount of activated carbon, is then inoculated in culture medium by chanterelle, after 37 DEG C of fermentation culture 42～48 days, clearly
Obtain chanterelle filament after washing culture medium, then mycelium is placed in 60～70 DEG C of baking ovens and dries to constant weight, smashed 100 mesh sieves
Obtain chicken oil mycelium powder.
Further, described antioxidant is disodiumedetate.Antioxidant mainly prevents ingredient from sending out
Raw oxidation deterioration, affects drug effect.
Further, described surfactant is tween 80.Surfactant acts primarily as the effect of solubilising, promotes each
Plant ingredient to dissolve each other.
Further, described isotonic agent is glycerol.Isotonic agent mainly regulates the osmotic pressure of body, promotes that cell is to medicine
The absorption of composition.
Another technical scheme of the present invention is to provide the system of a kind of compound eye drops for treating mycotic scleritis
Preparation Method, comprises the following steps:
(1) first surfactant and water for injection are added to preparation container stirring aquation 30～40min；
(2) successively by natamycin, chanterelle mycelium powder, Herba Emiliae alkaloid, taurine, jasminoidin, hyalomitome
Acid sodium, paeonol, Rhizoma Et Radix Notopterygii volatile oil, glycyrrhizic acid dipotassium, flucytosine, Radix Bupleuri total saponin, vitamin A, antioxidant join
(1), in, it is subsequently placed in ultrasonic disperse 40～60min in ultrasonic disperse instrument, obtains admixing medical solutions；
(3) isotonic agent is joined in (2), stir 10～20min, then stand 24～36h, filter, then by gained
Filtrate is in 0.1MPa, 120～130 DEG C of sterilization treatment 15～20min, and then subpackage i.e. obtains described compound eye drops.
Compared with prior art, beneficial effects of the present invention is embodied in: the compound eye drops of the present invention has stronger resisting
Fungi activity, and have the effect of Antipyretic, further enhances body anti-infection ability, improves immunity of organisms, wherein,
Natamycin, flucytosine have higher antifungal activity, and both anti-mycotic efficiencies that be combined with each other are more preferable；Herba Emiliae is biological
Alkali, jasminoidin, paeonol, Rhizoma Et Radix Notopterygii volatile oil, Radix Bupleuri total saponin have the effect of anti-inflammatory and antalgic, alleviate scleritis timely and effectively
The ocular pain caused, the most also has the antibacterial and effect of suppression allergy generation；Glycyrrhizic acid dipotassium has antiinflammatory, anti-mistake
Quick, effect of moisturizing, alleviates eye xerophthalmia puckery；Hyaluronate sodium mainly assists eyes to absorb other drug；Chanterelle
Mycelium powder contains abundant nutrient substance, have clear mesh, profit the effect such as lung, easy the intestines and stomach combine taurine, vitamin A improve
The immunity of body, obvious to the recovery effects of mycotic scleritis, safe secondary effect is little, has a extensive future.
Detailed description of the invention
Embodiment 1: the present embodiment prepares a kind of compound eye drops for treating mycotic scleritis, and one-tenth is grouped into:
Natamycin 0.01%, chanterelle mycelium powder 1%, Herba Emiliae alkaloid 0.1%, taurine 0.05%, jasminoidin
0.2%, hyaluronate sodium 0.6%, antioxidant 0.005%, surfactant 0.2%, isotonic agent 0.01%, surplus are injection
Use water.
Wherein, described chanterelle mycelium powder is to be pulverized prepared by chanterelle by the mycelium that fermentation culture generates.
Detailed process is: first by quality 1:1, Rhizoma Solani tuber osi and the Folium Pini of peeling stripping and slicing are joined the distilled water relative to Rhizoma Solani tuber osi 5 times amount
In boil, filter reserved filtrate and continue, be subsequently adding and dissolve relative to the agar of Rhizoma Solani tuber osi 1/10 and glucose, then exist
0.1MPa, 120 DEG C of sterilizing 30min, then preserve 24h at 37 DEG C, make culture medium, is subsequently adding PH regulator and adjusts PH to 6, adds
Enter a small amount of activated carbon, then chanterelle is inoculated in culture medium, after 37 DEG C of fermentation culture 42 days, obtain after cleaning culture medium
Obtain chanterelle filament, then mycelium is placed in 60 DEG C of baking ovens and dries to constant weight, smashed 100 mesh sieves and i.e. obtain chicken oil mycelium powder.
Wherein, described antioxidant is disodiumedetate.Antioxidant mainly prevents ingredient generation oxygen
Change rotten, affect drug effect.
Wherein, described surfactant is tween 80.Surfactant acts primarily as the effect of solubilising, promotes various medicine
Thing composition dissolves each other.
Wherein, described isotonic agent is glycerol.Isotonic agent mainly regulates the osmotic pressure of body, promotes that cell is to ingredient
Absorption.
The preparation method of a kind of compound eye drops for treating mycotic scleritis prepared by the present embodiment, including following
Step:
(1) first surfactant and water for injection are added to preparation container stirring aquation 30min；
(2) successively by natamycin, chanterelle mycelium powder, Herba Emiliae alkaloid, taurine, jasminoidin, hyalomitome
Acid sodium, antioxidant join in (1), are subsequently placed in ultrasonic disperse 40min in ultrasonic disperse instrument, obtain admixing medical solutions；
(3) isotonic agent is joined in (2), stir 10min, then stand 24h, filter, then gained filtrate is existed
0.1MPa, 120 DEG C of sterilization treatment 15min, then subpackage i.e. obtains described compound eye drops.
Embodiment 2: the present embodiment prepares a kind of compound eye drops for treating mycotic scleritis, and one-tenth is grouped into:
Natamycin 0.02%, chanterelle mycelium powder 1.5%, Herba Emiliae alkaloid 0.15%, taurine 0.065%, jasminoidin
0.3%, hyaluronate sodium 0.75%, antioxidant 0.007%, surfactant 0.3%, isotonic agent 0.015%, surplus are note
Penetrate and use water.
Wherein, described chanterelle mycelium powder is to be pulverized prepared by chanterelle by the mycelium that fermentation culture generates.
Detailed process is: first by quality 1:1, Rhizoma Solani tuber osi and the Folium Pini of peeling stripping and slicing are joined the distilled water relative to Rhizoma Solani tuber osi 5 times amount
In boil, filter reserved filtrate and continue, be subsequently adding and dissolve relative to the agar of Rhizoma Solani tuber osi 1/10 and glucose, then exist
0.1MPa, 120 DEG C of sterilizing 35min, then preserve 30h at 37 DEG C, make culture medium, is subsequently adding PH regulator and adjusts PH to 6, adds
Enter a small amount of activated carbon, then chanterelle is inoculated in culture medium, after 37 DEG C of fermentation culture 45 days, obtain after cleaning culture medium
Obtain chanterelle filament, then mycelium is placed in 65 DEG C of baking ovens and dries to constant weight, smashed 100 mesh sieves and i.e. obtain chicken oil mycelium powder.
Wherein, described antioxidant is disodiumedetate.Antioxidant mainly prevents ingredient generation oxygen
Change rotten, affect drug effect.
Wherein, described surfactant is tween 80.Surfactant acts primarily as the effect of solubilising, promotes various medicine
Thing composition dissolves each other.
Wherein, described isotonic agent is glycerol.Isotonic agent mainly regulates the osmotic pressure of body, promotes that cell is to ingredient
Absorption.
The preparation method of a kind of compound eye drops for treating mycotic scleritis prepared by the present embodiment, including following
Step:
(1) first surfactant and water for injection are added to preparation container stirring aquation 35min；
(2) successively by natamycin, chanterelle mycelium powder, Herba Emiliae alkaloid, taurine, jasminoidin, hyalomitome
Acid sodium, flucytosine, Radix Bupleuri total saponin, vitamin A, antioxidant join in (1), are subsequently placed in ultrasonic disperse instrument ultrasonic
Dispersion 50min, obtains admixing medical solutions；
(3) isotonic agent is joined in (2), stir 10～20min, then stand 30h, filter, then by gained filtrate
In 0.1MPa, 125 DEG C of sterilization treatment 17.5min, then subpackage i.e. obtains described compound eye drops.
Embodiment 3: the present embodiment prepares a kind of compound eye drops for treating mycotic scleritis, and one-tenth is grouped into:
Natamycin 0.03%, chanterelle mycelium powder 2%, Herba Emiliae alkaloid 0.2%, taurine 0.08%, jasminoidin
0.4%, hyaluronate sodium 0.9%, antioxidant 0.009%, surfactant 0.4%, isotonic agent 0.02%, surplus are injection
Use water.
Wherein, described chanterelle mycelium powder is to be pulverized prepared by chanterelle by the mycelium that fermentation culture generates.
Detailed process is: first by quality 1:1, Rhizoma Solani tuber osi and the Folium Pini of peeling stripping and slicing are joined the distilled water relative to Rhizoma Solani tuber osi 5 times amount
In boil, filter reserved filtrate and continue, be subsequently adding and dissolve relative to the agar of Rhizoma Solani tuber osi 1/10 and glucose, then exist
0.1MPa, 120 DEG C of sterilizing 40min, then preserve 36h at 37 DEG C, make culture medium, is subsequently adding PH regulator and adjusts PH to 6, adds
Enter a small amount of activated carbon, then chanterelle is inoculated in culture medium, after 37 DEG C of fermentation culture 48 days, obtain after cleaning culture medium
Obtain chanterelle filament, then mycelium is placed in 70 DEG C of baking ovens and dries to constant weight, smashed 100 mesh sieves and i.e. obtain chicken oil mycelium powder.
Wherein, described antioxidant is disodiumedetate.Antioxidant mainly prevents ingredient generation oxygen
Change rotten, affect drug effect.
Wherein, described surfactant is tween 80.Surfactant acts primarily as the effect of solubilising, promotes various medicine
Thing composition dissolves each other.
Wherein, described isotonic agent is glycerol.Isotonic agent mainly regulates the osmotic pressure of body, promotes that cell is to ingredient
Absorption.
The preparation method of a kind of compound eye drops for treating mycotic scleritis prepared by the present embodiment, including following
Step:
(1) first surfactant and water for injection are added to preparation container stirring aquation 40min；
(2) successively by natamycin, chanterelle mycelium powder, Herba Emiliae alkaloid, taurine, jasminoidin, hyalomitome
Acid sodium, antioxidant join in (1), are subsequently placed in ultrasonic disperse 60min in ultrasonic disperse instrument, obtain admixing medical solutions；
(3) isotonic agent is joined in (2), stir 20min, then stand 36h, filter, then gained filtrate is existed
0.1MPa, 130 DEG C of sterilization treatment 20min, then subpackage i.e. obtains described compound eye drops.
Embodiment 4: the present embodiment prepares a kind of compound eye drops for treating mycotic scleritis, and one-tenth is grouped into:
Natamycin 0.01%, chanterelle mycelium powder 1%, Herba Emiliae alkaloid 0.1%, taurine 0.05%, jasminoidin
0.2%, hyaluronate sodium 0.6%, paeonol 0.3%, Rhizoma Et Radix Notopterygii volatile oil 0.06%, glycyrrhizic acid dipotassium 0.12%, antioxidant
0.005%, surfactant 0.2%, isotonic agent 0.01%, surplus are water for injection.
Wherein, described chanterelle mycelium powder is to be pulverized prepared by chanterelle by the mycelium that fermentation culture generates.
Detailed process is: first by quality 1:1, Rhizoma Solani tuber osi and the Folium Pini of peeling stripping and slicing are joined the distilled water relative to Rhizoma Solani tuber osi 5 times amount
In boil, filter reserved filtrate and continue, be subsequently adding and dissolve relative to the agar of Rhizoma Solani tuber osi 1/10 and glucose, then exist
0.1MPa, 120 DEG C of sterilizing 30min, then preserve 24h at 37 DEG C, make culture medium, is subsequently adding PH regulator and adjusts PH to 6, adds
Enter a small amount of activated carbon, then chanterelle is inoculated in culture medium, after 37 DEG C of fermentation culture 42 days, obtain after cleaning culture medium
Obtain chanterelle filament, then mycelium is placed in 60 DEG C of baking ovens and dries to constant weight, smashed 100 mesh sieves and i.e. obtain chicken oil mycelium powder.
Wherein, described antioxidant is disodiumedetate.Antioxidant mainly prevents ingredient generation oxygen
Change rotten, affect drug effect.
Wherein, described surfactant is tween 80.Surfactant acts primarily as the effect of solubilising, promotes various medicine
Thing composition dissolves each other.
Wherein, described isotonic agent is glycerol.Isotonic agent mainly regulates the osmotic pressure of body, promotes that cell is to ingredient
Absorption.
The preparation method of a kind of compound eye drops for treating mycotic scleritis prepared by the present embodiment, including following
Step:
(1) first surfactant and water for injection are added to preparation container stirring aquation 30min；
(2) successively by natamycin, chanterelle mycelium powder, Herba Emiliae alkaloid, taurine, jasminoidin, hyalomitome
Acid sodium, paeonol, Rhizoma Et Radix Notopterygii volatile oil, glycyrrhizic acid dipotassium, antioxidant join in (1), are subsequently placed in ultrasonic disperse instrument super
Sound dispersion 40min, obtains admixing medical solutions；
(3) isotonic agent is joined in (2), stir 10min, then stand 24h, filter, then gained filtrate is existed
0.1MPa, 120 DEG C of sterilization treatment 15min, then subpackage i.e. obtains described compound eye drops.
Embodiment 5: the present embodiment prepares a kind of compound eye drops for treating mycotic scleritis, and one-tenth is grouped into:
Natamycin 0.02%, chanterelle mycelium powder 1.5%, Herba Emiliae alkaloid 0.15%, taurine 0.065%, jasminoidin
0.3%, hyaluronate sodium 0.75%, paeonol 0.5%, Rhizoma Et Radix Notopterygii volatile oil 0.075%, glycyrrhizic acid dipotassium 0.18%, antioxidation
Agent 0.007%, surfactant 0.3%, isotonic agent 0.015%, surplus are water for injection.
Wherein, described chanterelle mycelium powder is to be pulverized prepared by chanterelle by the mycelium that fermentation culture generates.
Detailed process is: first by quality 1:1, Rhizoma Solani tuber osi and the Folium Pini of peeling stripping and slicing are joined the distilled water relative to Rhizoma Solani tuber osi 5 times amount
In boil, filter reserved filtrate and continue, be subsequently adding and dissolve relative to the agar of Rhizoma Solani tuber osi 1/10 and glucose, then exist
0.1MPa, 120 DEG C of sterilizing 35min, then preserve 30h at 37 DEG C, make culture medium, is subsequently adding PH regulator and adjusts PH to 6, adds
Enter a small amount of activated carbon, then chanterelle is inoculated in culture medium, after 37 DEG C of fermentation culture 45 days, obtain after cleaning culture medium
Obtain chanterelle filament, then mycelium is placed in 65 DEG C of baking ovens and dries to constant weight, smashed 100 mesh sieves and i.e. obtain chicken oil mycelium powder.
Wherein, described antioxidant is disodiumedetate.Antioxidant mainly prevents ingredient generation oxygen
Change rotten, affect drug effect.
Wherein, described surfactant is tween 80.Surfactant acts primarily as the effect of solubilising, promotes various medicine
Thing composition dissolves each other.
Wherein, described isotonic agent is glycerol.Isotonic agent mainly regulates the osmotic pressure of body, promotes that cell is to ingredient
Absorption.
The preparation method of a kind of compound eye drops for treating mycotic scleritis prepared by the present embodiment, including following
Step:
(1) first surfactant and water for injection are added to preparation container stirring aquation 35min；
(2) successively by natamycin, chanterelle mycelium powder, Herba Emiliae alkaloid, taurine, jasminoidin, hyalomitome
Acid sodium, paeonol, Rhizoma Et Radix Notopterygii volatile oil, glycyrrhizic acid dipotassium, antioxidant join in (1), are subsequently placed in ultrasonic disperse instrument super
Sound dispersion 50min, obtains admixing medical solutions；
(3) isotonic agent is joined in (2), stir 10～20min, then stand 30h, filter, then by gained filtrate
In 0.1MPa, 125 DEG C of sterilization treatment 17.5min, then subpackage i.e. obtains described compound eye drops.
Embodiment 6: the present embodiment prepares a kind of compound eye drops for treating mycotic scleritis, and one-tenth is grouped into:
Natamycin 0.03%, chanterelle mycelium powder 2%, Herba Emiliae alkaloid 0.2%, taurine 0.08%, jasminoidin
0.4%, hyaluronate sodium 0.9%, paeonol 0.4%, Rhizoma Et Radix Notopterygii volatile oil 0.09%, glycyrrhizic acid dipotassium 0.24%, antioxidant
0.009%, surfactant 0.4%, isotonic agent 0.02%, surplus are water for injection.
Wherein, described chanterelle mycelium powder is to be pulverized prepared by chanterelle by the mycelium that fermentation culture generates.
Detailed process is: first by quality 1:1, Rhizoma Solani tuber osi and the Folium Pini of peeling stripping and slicing are joined the distilled water relative to Rhizoma Solani tuber osi 5 times amount
In boil, filter reserved filtrate and continue, be subsequently adding and dissolve relative to the agar of Rhizoma Solani tuber osi 1/10 and glucose, then exist
0.1MPa, 120 DEG C of sterilizing 40min, then preserve 36h at 37 DEG C, make culture medium, is subsequently adding PH regulator and adjusts PH to 6, adds
Enter a small amount of activated carbon, then chanterelle is inoculated in culture medium, after 37 DEG C of fermentation culture 48 days, obtain after cleaning culture medium
Obtain chanterelle filament, then mycelium is placed in 70 DEG C of baking ovens and dries to constant weight, smashed 100 mesh sieves and i.e. obtain chicken oil mycelium powder.
Wherein, described antioxidant is disodiumedetate.Antioxidant mainly prevents ingredient generation oxygen
Change rotten, affect drug effect.
Wherein, described surfactant is tween 80.Surfactant acts primarily as the effect of solubilising, promotes various medicine
Thing composition dissolves each other.
Wherein, described isotonic agent is glycerol.Isotonic agent mainly regulates the osmotic pressure of body, promotes that cell is to ingredient
Absorption.
The preparation method of a kind of compound eye drops for treating mycotic scleritis prepared by the present embodiment, including following
Step:
(1) first surfactant and water for injection are added to preparation container stirring aquation 40min；
(2) successively by natamycin, chanterelle mycelium powder, Herba Emiliae alkaloid, taurine, jasminoidin, hyalomitome
Acid sodium, paeonol, Rhizoma Et Radix Notopterygii volatile oil, glycyrrhizic acid dipotassium, antioxidant join in (1), are subsequently placed in ultrasonic disperse instrument super
Sound dispersion 60min, obtains admixing medical solutions；
(3) isotonic agent is joined in (2), stir 20min, then stand 36h, filter, then gained filtrate is existed
0.1MPa, 130 DEG C of sterilization treatment 20min, then subpackage i.e. obtains described compound eye drops.
Embodiment 7: the present embodiment prepares a kind of compound eye drops for treating mycotic scleritis, and one-tenth is grouped into:
Natamycin 0.01%, chanterelle mycelium powder 1%, Herba Emiliae alkaloid 0.1%, taurine 0.05%, jasminoidin
0.2%, hyaluronate sodium 0.6%, paeonol 0.3%, Rhizoma Et Radix Notopterygii volatile oil 0.06%, glycyrrhizic acid dipotassium 0.12%, flucytosine
0.02%, Radix Bupleuri total saponin 0.2%, dehydroretinol %, antioxidant 0.005%, surfactant 0.2%, isotonic agent
0.01%, surplus is water for injection.
Wherein, described chanterelle mycelium powder is to be pulverized prepared by chanterelle by the mycelium that fermentation culture generates.
Detailed process is: first by quality 1:1, Rhizoma Solani tuber osi and the Folium Pini of peeling stripping and slicing are joined the distilled water relative to Rhizoma Solani tuber osi 5 times amount
In boil, filter reserved filtrate and continue, be subsequently adding and dissolve relative to the agar of Rhizoma Solani tuber osi 1/10 and glucose, then exist
0.1MPa, 120 DEG C of sterilizing 30min, then preserve 24h at 37 DEG C, make culture medium, is subsequently adding PH regulator and adjusts PH to 6, adds
Enter a small amount of activated carbon, then chanterelle is inoculated in culture medium, after 37 DEG C of fermentation culture 42 days, obtain after cleaning culture medium
Obtain chanterelle filament, then mycelium is placed in 60 DEG C of baking ovens and dries to constant weight, smashed 100 mesh sieves and i.e. obtain chicken oil mycelium powder.
Wherein, described antioxidant is disodiumedetate.Antioxidant mainly prevents ingredient generation oxygen
Change rotten, affect drug effect.
Wherein, described surfactant is tween 80.Surfactant acts primarily as the effect of solubilising, promotes various medicine
Thing composition dissolves each other.
Wherein, described isotonic agent is glycerol.Isotonic agent mainly regulates the osmotic pressure of body, promotes that cell is to ingredient
Absorption.
The preparation method of a kind of compound eye drops for treating mycotic scleritis prepared by the present embodiment, including following
Step:
(1) first surfactant and water for injection are added to preparation container stirring aquation 30min；
(2) successively by natamycin, chanterelle mycelium powder, Herba Emiliae alkaloid, taurine, jasminoidin, hyalomitome
Acid sodium, paeonol, Rhizoma Et Radix Notopterygii volatile oil, glycyrrhizic acid dipotassium, flucytosine, Radix Bupleuri total saponin, vitamin A, antioxidant join
(1), in, it is subsequently placed in ultrasonic disperse 40min in ultrasonic disperse instrument, obtains admixing medical solutions；
(3) isotonic agent is joined in (2), stir 10min, then stand 24h, filter, then gained filtrate is existed
0.1MPa, 120 DEG C of sterilization treatment 15min, then subpackage i.e. obtains described compound eye drops.
Embodiment 8: the present embodiment prepares a kind of compound eye drops for treating mycotic scleritis, and one-tenth is grouped into:
Natamycin 0.02%, chanterelle mycelium powder 1.5%, Herba Emiliae alkaloid 0.15%, taurine 0.065%, jasminoidin
0.3%, hyaluronate sodium 0.75%, paeonol 0.5%, Rhizoma Et Radix Notopterygii volatile oil 0.075%, glycyrrhizic acid dipotassium 0.18%, fluorine born of the same parents are phonetic
Pyridine 0.025%, Radix Bupleuri total saponin 0.3%, 3-Hydroxyretinol %, antioxidant 0.007%, surfactant 0.3%, isotonic agent
0.015%, surplus is water for injection.
Wherein, described chanterelle mycelium powder is to be pulverized prepared by chanterelle by the mycelium that fermentation culture generates.
Detailed process is: first by quality 1:1, Rhizoma Solani tuber osi and the Folium Pini of peeling stripping and slicing are joined the distilled water relative to Rhizoma Solani tuber osi 5 times amount
In boil, filter reserved filtrate and continue, be subsequently adding and dissolve relative to the agar of Rhizoma Solani tuber osi 1/10 and glucose, then exist
0.1MPa, 120 DEG C of sterilizing 35min, then preserve 30h at 37 DEG C, make culture medium, is subsequently adding PH regulator and adjusts PH to 6, adds
Enter a small amount of activated carbon, then chanterelle is inoculated in culture medium, after 37 DEG C of fermentation culture 45 days, obtain after cleaning culture medium
Obtain chanterelle filament, then mycelium is placed in 65 DEG C of baking ovens and dries to constant weight, smashed 100 mesh sieves and i.e. obtain chicken oil mycelium powder.
Wherein, described antioxidant is disodiumedetate.Antioxidant mainly prevents ingredient generation oxygen
Change rotten, affect drug effect.
Wherein, described surfactant is tween 80.Surfactant acts primarily as the effect of solubilising, promotes various medicine
Thing composition dissolves each other.
Wherein, described isotonic agent is glycerol.Isotonic agent mainly regulates the osmotic pressure of body, promotes that cell is to ingredient
Absorption.
The preparation method of a kind of compound eye drops for treating mycotic scleritis prepared by the present embodiment, including following
Step:
(1) first surfactant and water for injection are added to preparation container stirring aquation 35min；
(2) successively by natamycin, chanterelle mycelium powder, Herba Emiliae alkaloid, taurine, jasminoidin, hyalomitome
Acid sodium, paeonol, Rhizoma Et Radix Notopterygii volatile oil, glycyrrhizic acid dipotassium, flucytosine, Radix Bupleuri total saponin, vitamin A, antioxidant join
(1), in, it is subsequently placed in ultrasonic disperse 50min in ultrasonic disperse instrument, obtains admixing medical solutions；
(3) isotonic agent is joined in (2), stir 10～20min, then stand 30h, filter, then by gained filtrate
In 0.1MPa, 125 DEG C of sterilization treatment 17.5min, then subpackage i.e. obtains described compound eye drops.
Embodiment 9: the present embodiment prepares a kind of compound eye drops for treating mycotic scleritis, and one-tenth is grouped into:
Natamycin 0.03%, chanterelle mycelium powder 2%, Herba Emiliae alkaloid 0.2%, taurine 0.08%, jasminoidin
0.4%, hyaluronate sodium 0.9%, paeonol 0.4%, Rhizoma Et Radix Notopterygii volatile oil 0.09%, glycyrrhizic acid dipotassium 0.24%, flucytosine
0.03%, Radix Bupleuri total saponin 0.4%, vitamin A 4%, antioxidant 0.009%, surfactant 0.4%, isotonic agent
0.02%, surplus is water for injection.
Wherein, described chanterelle mycelium powder is to be pulverized prepared by chanterelle by the mycelium that fermentation culture generates.
Detailed process is: first by quality 1:1, Rhizoma Solani tuber osi and the Folium Pini of peeling stripping and slicing are joined the distilled water relative to Rhizoma Solani tuber osi 5 times amount
In boil, filter reserved filtrate and continue, be subsequently adding and dissolve relative to the agar of Rhizoma Solani tuber osi 1/10 and glucose, then exist
0.1MPa, 120 DEG C of sterilizing 40min, then preserve 36h at 37 DEG C, make culture medium, is subsequently adding PH regulator and adjusts PH to 6, adds
Enter a small amount of activated carbon, then chanterelle is inoculated in culture medium, after 37 DEG C of fermentation culture 48 days, obtain after cleaning culture medium
Obtain chanterelle filament, then mycelium is placed in 70 DEG C of baking ovens and dries to constant weight, smashed 100 mesh sieves and i.e. obtain chicken oil mycelium powder.
Wherein, described antioxidant is disodiumedetate.Antioxidant mainly prevents ingredient generation oxygen
Change rotten, affect drug effect.
Wherein, described surfactant is tween 80.Surfactant acts primarily as the effect of solubilising, promotes various medicine
Thing composition dissolves each other.
Wherein, described isotonic agent is glycerol.Isotonic agent mainly regulates the osmotic pressure of body, promotes that cell is to ingredient
Absorption.
The preparation method of a kind of compound eye drops for treating mycotic scleritis prepared by the present embodiment, including following
Step:
(1) first surfactant and water for injection are added to preparation container stirring aquation 40min；
(2) successively by natamycin, chanterelle mycelium powder, Herba Emiliae alkaloid, taurine, jasminoidin, hyalomitome
Acid sodium, paeonol, Rhizoma Et Radix Notopterygii volatile oil, glycyrrhizic acid dipotassium, flucytosine, Radix Bupleuri total saponin, vitamin A, antioxidant join
(1), in, it is subsequently placed in ultrasonic disperse 60min in ultrasonic disperse instrument, obtains admixing medical solutions；
(3) isotonic agent is joined in (2), stir 20min, then stand 36h, filter, then gained filtrate is existed
0.1MPa, 130 DEG C of sterilization treatment 20min, then subpackage i.e. obtains described compound eye drops.
Experimental verification
One, animal toxicity test
1. animal selects: select 200 healthy rats, then subconjunctival injection aspergillosis, per injection 3ml, continuously
Inject one month, make mice all occur being envious, photophobia, shed tears, the symptom such as ophthalmalgia, visual deterioration and conjunctival sac secretions.Then
Rat is randomly divided into 4 groups, is designated as 1 group, 2 groups, 3 groups, 4 groups respectively, often group 50.
2. test method: the eye drop of the 1 group of rat eye instillation embodiment of the present invention 2 preparation, each 2～3；2 groups big
The eye drop of the rathole eyeball instillation embodiment of the present invention 5 preparation, each 2～3；3 groups of rat eye instillation embodiment of the present invention 8 are made
Standby eye drop, each 2～3；The eye drop of the 4 groups of rat instillation embodiment of the present invention 8 preparations, each 10～15.Wherein 1
～3 groups drip 7 days continuously, 4 groups drip 30 days continuously, drip three every day.
3. result of the test: each group rat does not occurs other symptoms within experimental period, and does not all have death.Wherein 1～3 group big
The rathole eyeball redness blood streak is decorporated, no longer photophobia, gives a test of one's eyesight and also recovers normal, and conjunctiva no longer secretes foreign body, and laboratory is examined
The eye looking into rat has no fungal infection.4 groups of various symptoms of rat all take a turn for the better, and the eye of lab testing rat has no fungus sense
Dye, dissects 4 groups of rats, has no any organ injury caused due to eye drop excess.
Two. clinical treatment is verified
1. case selection: inventor selects patient 120 people suffering from mycotic scleritis that certain ophthalmologic hospital clinic is accepted for medical treatment,
It is randomly divided into 4 groups, often organizes 30 people, wherein experimental group 3 groups, matched group 1 group.Each group patient, without significant difference, has comparability.
2. Therapeutic Method: experimental group patient is respectively to the eye drop of the eyes instillation embodiment of the present invention 2,5,8 preparation, every time
Dripping 2～3, drip every day 3 times, matched group patient instils oxygen Buddhist sand star eye drop, each 2～3, three times a day, drips 7 days continuously.
3. criterion of therapeutical effect:
Recovery from illness: eyes redness is decorporated, no longer photophobia, vision restoration is normal, no longer secretes foreign body；
Effective: eyes redness is decorporated, no longer photophobia, vision restoration is normal, accidental secretion foreign body；
Invalid: all symptoms are not all improved.
4. therapeutic outcome:
| Group | Case/example | Recovery from illness/example | Effectively/example | Invalid/example | Effective percentage/% |
| Embodiment 2 | 30 | 26 | 1 | 3 | 90 |
| Embodiment 5 | 30 | 26 | 2 | 2 | 93.3 |
| Embodiment 8 | 30 | 28 | 1 | 1 | 96.7 |
| Matched group | 30 | 24 | 2 | 4 | 86.7 |
5. conclusion: have clinical treatment case it can be seen that the compound recipe eye drip for treating mycotic scleritis of the present invention
Liquid not only has good antifungic action, and clinical effectiveness is notable, and effective percentage reaches more than 90%, and toxic and side effects is little, suitable
Preferably promote the use of.
Although the present invention being described and illustrated with reference to its specific embodiments, but it will be appreciated by those skilled in the art that
Without departing from the spirit and scope of the present invention it can be variously modified, revise and replace.Such as, due to quilt
The change of the responding ability of the people for the treatment of particular condition, the effective dose beyond preferred dose as explained above may be suitable for.With
Sample ground, it was observed that pharmacology respond may basis and rely on selected particular active compounds or whether exist pharmaceutical carrier and
Preparation type and mode of administration used and become, this kind of expection change that is contemplated in result according to the purpose of the present invention and practice or
Difference.Therefore, the invention is intended to only to be limited by the scope of following claims and these claim should be in rational degree
Explain as broadly as possible.
Claims (8)
1. the compound eye drops being used for treating mycotic scleritis, it is characterised in that described compound eye drops becomes packet
Become: natamycin 0.01～0.03%, chanterelle mycelium powder 1～2%, Herba Emiliae alkaloid 0.1～0.2%, amino second sulphur
Acid 0.05～0.08%, jasminoidin 0.2～0.4%, hyaluronate sodium 0.6～0.9%, antioxidant 0.005～0.009%,
Surfactant 0.2～0.4%, isotonic agent 0.01～0.02%, surplus are water for injection.
A kind of compound eye drops for treating mycotic scleritis, it is characterised in that described
Compound eye drops becomes to be grouped into and also include: paeonol 0.3～0.4%, Rhizoma Et Radix Notopterygii volatile oil 0.06～0.09%, glycyrrhizic acid dipotassium
0.12～0.24%.
A kind of compound eye drops for treating mycotic scleritis, it is characterised in that described
Compound eye drops becomes to be grouped into and also include: flucytosine 0.02～0.03%, Radix Bupleuri total saponin 0.2～0.4%, vitamin A 2
～4%.
A kind of compound eye drops for treating mycotic scleritis, it is characterised in that described
Chanterelle mycelium powder is to be pulverized prepared by chanterelle by the mycelium that fermentation culture generates.
A kind of compound eye drops for treating mycotic scleritis, it is characterised in that described
Antioxidant is sodium ethylene diamine tetracetate.
A kind of compound eye drops for treating mycotic scleritis, it is characterised in that described
Surfactant is tween 80.
A kind of compound eye drops for treating mycotic scleritis, it is characterised in that described
Isotonic agent is glycerol.
A kind of preparation method of the compound eye drops for treating mycotic scleritis, its feature
It is, including comprising the following steps:
(1) first surfactant and water for injection are added to preparation container stirring aquation 30～40min.
(2) successively by natamycin, chanterelle mycelium powder, Herba Emiliae alkaloid, taurine, jasminoidin, hyaluronate sodium,
Paeonol, Rhizoma Et Radix Notopterygii volatile oil, glycyrrhizic acid dipotassium, flucytosine, Radix Bupleuri total saponin, vitamin A, antioxidant join in (1),
It is subsequently placed in ultrasonic disperse 40～60min in ultrasonic disperse instrument, obtains admixing medical solutions.
(3) isotonic agent is joined in (2), stir 10～20min, then stand 24～36h, filter, then by gained filtrate
In 0.1MPa, 120～130 DEG C of sterilization treatment 15～20min, then subpackage i.e. obtains described compound eye drops.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610790882.5A CN106214717A (en) | 2016-08-31 | 2016-08-31 | A kind of for compound eye drops treating mycotic scleritis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610790882.5A CN106214717A (en) | 2016-08-31 | 2016-08-31 | A kind of for compound eye drops treating mycotic scleritis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106214717A true CN106214717A (en) | 2016-12-14 |
Family
ID=58074479
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610790882.5A Pending CN106214717A (en) | 2016-08-31 | 2016-08-31 | A kind of for compound eye drops treating mycotic scleritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106214717A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110664752A (en) * | 2019-10-28 | 2020-01-10 | 哈尔滨医科大学科技开发总公司 | Natamycin polymer micelle eye drops and preparation method thereof |
| CN113491667A (en) * | 2021-07-22 | 2021-10-12 | 陕西省眼科研究所 | Dipotassium glycyrrhizinate ophthalmic preparation and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101385703A (en) * | 2008-10-01 | 2009-03-18 | 山东省眼科研究所 | Cation adhesion type natamycin nano eye drops |
| CN103070948A (en) * | 2012-11-07 | 2013-05-01 | 山东施尔明眼科医院 | Pharmaceutical composition for treating eye diseases and preparation method |
-
2016
- 2016-08-31 CN CN201610790882.5A patent/CN106214717A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101385703A (en) * | 2008-10-01 | 2009-03-18 | 山东省眼科研究所 | Cation adhesion type natamycin nano eye drops |
| CN103070948A (en) * | 2012-11-07 | 2013-05-01 | 山东施尔明眼科医院 | Pharmaceutical composition for treating eye diseases and preparation method |
Non-Patent Citations (5)
| Title |
|---|
| 南京铁道医学院主编: "《眼科学》", 28 February 1976 * |
| 周珊: ""中西医结合治疗真菌性角膜炎28例"", 《中医研究》 * |
| 张仁俊主编: "《实用眼科药物学》", 30 September 2015 * |
| 李如光主编: "《吉林省真菌志 第1卷 担子菌亚门》", 31 July 1991 * |
| 王清秀等: ""那他霉素治疗真菌性角膜溃疡的观察与护理"", 《实用护理杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110664752A (en) * | 2019-10-28 | 2020-01-10 | 哈尔滨医科大学科技开发总公司 | Natamycin polymer micelle eye drops and preparation method thereof |
| CN110664752B (en) * | 2019-10-28 | 2021-06-29 | 哈尔滨医科大学科技开发总公司 | Natamycin polymer micelle eye drops and preparation method thereof |
| CN113491667A (en) * | 2021-07-22 | 2021-10-12 | 陕西省眼科研究所 | Dipotassium glycyrrhizinate ophthalmic preparation and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109091675B (en) | Compound low-concentration atropine medicine eye drops and preparation method thereof | |
| CN108904633A (en) | A kind of eye ointment and preparation method thereof improving eyesight | |
| CN111544390B (en) | Traditional Chinese medicine preparation for treating meibomian gland dysfunction and/or allergic conjunctivitis, ultrasonic atomization and nano-spray preparation and preparation method | |
| CN106214717A (en) | A kind of for compound eye drops treating mycotic scleritis and preparation method thereof | |
| CN105106318B (en) | A kind of Chinese medicine composition and preparation method thereof for treating xerophthalmia | |
| Heydari et al. | Crocin as a vision supplement | |
| CN114869885A (en) | Preparation of honokiol ophthalmic medicine and application of honokiol ophthalmic medicine in fungal keratitis treatment | |
| CN108125996A (en) | It is a kind of for visual fatigue, dry eyes eye-drops preparations | |
| CN102526171B (en) | Eye health care product capable of preventing and delaying senile macular degeneration and manufacture method | |
| CN102872335B (en) | Externally used Chinese medicine preparation for curing diabetic foot and preparation method thereof | |
| CN105326954B (en) | A kind of Chinese medicine composition and preparation method thereof for treating blear-eye | |
| CN104906220A (en) | Traditional Chinese medicine for treating herpes zoster and herpes simplex viral keratitis | |
| CN108815175A (en) | A kind of spray that eye is applied outside | |
| CN105232640A (en) | Method of using cistanche tubulosa extract for preparing drugs or food to protect eye cells | |
| CN105326955B (en) | A kind of composition and preparation method thereof for treating blear-eye | |
| CN108078868A (en) | A kind of antiallergic composition for skin care item | |
| CN106334024A (en) | Traditional Chinese medicine preparation for treating lower extremity thrombophlebitis | |
| CN113713022A (en) | Eye protection liquid and preparation method and application thereof | |
| CN107260802A (en) | Coronary heart disease drop pill is used for the new application for preventing and treating diabetic complication | |
| RU2495669C1 (en) | Method of treating degenerative and dystrophic retinal diseases | |
| CN106540170A (en) | A kind of Chinese medicine for treating the bleeding eye diseases such as macular degeneration, retinal vein obstruction | |
| Huang | Chakras energy deficiency as the cause of chronic conjunctival hyperemia | |
| CN111110817A (en) | Traditional Chinese medicine composition for treating eye diseases, preparation method and application thereof | |
| CN110448581A (en) | A kind of drug containing Lythrum salicaria liquid and its purposes in the drug of preparation treatment burn and scald | |
| CN105726698B (en) | Rose composition and eye mask for relieving visual fatigue and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161214 |